Voltaren Arthritis Pain Gel: OTC relief option from Novartis heritage portfolio

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 11:11 PM ET. Details in the imprint.

Voltaren Arthritis Pain Gel is a topical nonsteroidal anti-inflammatory drug (NSAID) designed to relieve osteoarthritis pain in joints such as knees, ankles, feet, elbows, wrists, and hands in adults 18 years and older. In the United States, it is available over the counter (OTC) in strengths such as 1% diclofenac sodium gel, allowing consumers to use a prescription-strength active ingredient without a prescription under labeled directions. The gel format aims to deliver the anti-inflammatory effect directly to the painful joint area, which can be appealing to users who want to limit systemic exposure associated with oral NSAIDs.

What Voltaren Arthritis Pain Gel does and how it is used

Voltaren Arthritis Pain Gel is indicated for the temporary relief of arthritis pain in specific joints, with directions that typically limit use to the affected area up to four times a day for no more than 21 days unless directed by a doctor. The active ingredient, diclofenac sodium, works by inhibiting cyclooxygenase (COX) enzymes involved in prostaglandin synthesis, which play a key role in inflammation and pain signaling in arthritic joints. Because the gel is applied to the skin over the joint, it provides a localized therapy option that may be useful for adults who cannot tolerate or wish to avoid high-dose oral NSAIDs due to gastrointestinal or cardiovascular risk concerns that are described in NSAID class warnings. As with other NSAIDs, however, the label also includes cautions about possible systemic effects and advises consumers with risk factors or underlying conditions to consult a healthcare professional before use.

The product is typically sold in measured-dose tubes that support accurate application, with dosing guides in grams so users can match the amount of gel to the size of the joint and ensure they are staying within the maximum daily dose on the label. Gels like Voltaren are often formulated with excipients that help the active ingredient penetrate the outer layers of the skin and reach tissues around the joint, while still drying relatively quickly so the product does not interfere excessively with clothing or daily activities. For many users, this format can be integrated into a daily routine alongside non-pharmacologic measures such as physical therapy, gentle exercise, or joint supports as recommended by clinicians.

In the broader consumer health landscape, topical arthritis products compete with oral analgesics, heat and cold therapies, and other creams containing ingredients such as capsaicin or menthol. Voltaren Arthritis Pain Gel is differentiated by its NSAID mechanism and by clinical data that demonstrate pain relief in osteoarthritis when used as directed, which is highlighted in consumer-facing materials and on-pack claims where regulations permit. For adult users managing chronic joint pain, the option to treat a specific joint without swallowing a pill can be a key buying factor, especially among older consumers who may already be taking multiple oral medications for other conditions.

In the US retail channel, Voltaren Arthritis Pain Gel is distributed in major pharmacy chains, grocery stores, mass retailers, and online outlets that carry OTC medicines. It is positioned as a branded alternative to store-brand diclofenac gels, with marketing emphasizing brand recognition, quality controls, and the backing of a large global healthcare company. Packaging typically includes clear usage diagrams and warnings in line with FDA OTC drug labeling requirements, helping consumers understand where the product can be applied and when medical advice is needed before or during use.

From a portfolio perspective, Voltaren traces back to Novartis and GSK consumer health roots and is today globally associated with Haleon as an over-the-counter brand, while Novartis AG focuses on its innovative medicines and pharmaceutical pipeline. For investors following that pipeline, Novartis AG (CH0012005267, ticker NVS) last traded at $148.45 on the NYSE on June 12, 2026.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.